A Study of Single Ascending Doses of VIB1116 in Rheumatic Diseases
Status:
Recruiting
Trial end date:
2022-12-15
Target enrollment:
Participant gender:
Summary
A first-in-human study to evaluate the safety and tolerability of escalating, single
subcutaneous or IV doses of VIB1116 in adult participants with rheumatic diseases.